Monon Bioventures will be partnering with fellow ICBI company, Genezen, and the Purdue University College of Pharmacy to study the feasibility of manufacturing a glioblastoma therapeutic using human immune natural killer (NK) cells, a therapeutic created at the Purdue University College of Pharmacy.